ASCLF News and Press, Ascletis Pharma Inc. From 06/13/21

Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. Beijing's BeiGene presented positive interim results from Phase III trial that compared its BTK candidate to AbbVie's Imbruv...

NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. Esco Lifesciences of Singapore, an Asia-based life sciences tools company, closed an over-subscribed $200 million Series A and crossover round. Suzhou's...

The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian ...

Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement. Junshi Biosciences and Eli Lilly announ...

DXY.cn, a China healthcare platform, raised $500 million in an E round. Zai Lab in-licensed China rights to a next-gen EGFR inhibitor aimed at cells expressing mutant EGFR variants from Boston's Cullinan Oncology in an agreement worth up to $233 million. Hutchison China MediTech a...

The FDA designates Fast Track designation to Gannex's, a unit of Ascletis Pharma ([[ASCLF]]) ASC42 for the treatment non-alcoholic steatohepatitis.ASC42 is an in-house developed，novel non-steroidal, selective, potent Farnesoid X Receptor agonist. For further detai...

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million. Singapore's ASLAN Pharmaceuticals announced plans to develop ASLAN003, its next-gen dihydroorotate dehydrogenase inhibitor in autoimmune conditions, such as multiple sclerosis. ...

Deals and Financings Baidu (BIDU), one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company. It believes the $2 billion fundraising will take two years to complete. The new company plans to...

Galmed Pharmaceuticals (NASDAQ: GLMD )  anf Gannex Pharma, a wholly owned company of Ascletis Pharma Inc. ( OTCPK:ASCLF )  have entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of n...

Deals and Financings Suzhou Innovent Bio (IVBIY) [HK:01801] expanded its 2015 alliance with Eli Lilly (LLY) for Tyvyt ® , Innovent's anti-PD-1 immunotherapy (see story ). In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets. Lil...